Department of Surgery, Pirogov Russian National Research Medical University, Moscow, Russian Federation.
Future Cardiol. 2022 Sep;18(10):777-785. doi: 10.2217/fca-2022-0026. Epub 2022 Aug 25.
To investigate the effectiveness and tolerability of adjunctive micronized purified flavonoid fraction (MPFF) in patients with chronic venous disease (CVD). This observational study included adults (≥18 years) with clinical-etiology-anatomy-pathophysiology (CEAP) class C4 CVD for whom MPFF was indicated. Outcomes included changes in subcutaneous adipose thickness, venous clinical severity score, CVD symptoms (using a visual analogue scale) and tolerability. Of 381 patients, 365 completed the study. After 6 months, subcutaneous adipose tissue thickness, venous clinical severity score and visual analogue scale scores significantly improved (all p < 0.001 vs baseline). No adverse drug reactions occurred. Adjunctive MPFF treatment improves skin and subcutaneous tissue conditions in CVD patients. NCT04138576 (ClinicalTrials.gov).
研究辅助应用微粉化纯化黄酮类混合物（MPFF）治疗慢性静脉疾病（CVD）的有效性和耐受性。
这是一项观察性研究，纳入了临床病因解剖病理生理学（CEAP）分级为 C4 期 CVD 的成年患者（≥18 岁），这些患者需要应用 MPFF 进行治疗。研究的主要终点包括皮下脂肪厚度、静脉临床严重程度评分、CVD 症状（采用视觉模拟评分法）和耐受性的变化。
381 例患者中，365 例完成了研究。治疗 6 个月后，皮下脂肪组织厚度、静脉临床严重程度评分和视觉模拟评分显著改善（均 p＜0.001）。未发生药物不良反应。
辅助应用 MPFF 可改善 CVD 患者的皮肤和皮下组织状况。
NCT04138576（ClinicalTrials.gov）。
